Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia.
Bottom Line: Plasma levels of interleukin (IL)-17, IL-22, IL-23, IL-1β, IL-6, and transforming growth factor (TGF)-β1 were significantly increased in blood and bone marrow in AML patients compared with healthy donors.Patients with high Th17 cell frequency had poor prognosis, whereas patients with high Th1 cell frequency had prolonged survival.Combined analysis of Th1 and Th17 cell frequencies improved the ability to predict patient outcomes.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Show MeSH
Related in: MedlinePlus
Mentions: Higher Th17 cell frequencies in AML patients compared with those in healthy donors were shown, which provoked our interests to examine the phenotype of Th17 cells in BM, a tumor microenvironment. As shown in Figure 2(a), we found that IL-17A was mainly produced by T cells rather than B cells. The majority of tumor-infiltrating IL-17A+ T cells were IL-17A+CD4+ (Th17) cells but not IL-17A+CD8+ cells. Tumor-infiltrating Th17 cells express high levels of CCR6 and negligible levels of HLA-DR, CD25, and CD62L (Fig. 2b). CCR6 is a surface receptor of Th17 cells and Th17 cells can be migrated towards tumor in a CCR6/CCL20 dependent manner, which leads to an enrichment of Th17 cells in the tumor microenvironment.(24) We also observed that Tumor-infiltrating Th17 cells were mainly CD4+CD45RO+ memory T cells, but not CD4+CD45RA+ naive T cells.
Affiliation: Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.